Supplement Scholar
Metabolic / GLP-1

Tirzepatide

Research compound. This is not a dietary supplement. Unless it is identified as an approved prescription drug, it is not approved by the FDA for human use. This page summarizes published research for education only; we do not sell it or link to sellers.

Tirzepatide. Dual GIP and GLP-1 receptor agonist with stronger weight-loss effects than GLP-1 alone.

How it works. Co-activates GIP and GLP-1 receptors, producing additive insulinotropic, satiety, and adipose-tissue effects greater than GLP-1 alone.

What the research supports. 3 graded claims. Strongest: Largest documented weight loss for an injectable peptide therapy (preclinical).

Hormonal impact. Effects on Insulin, Glucagon, GIP signaling, Leptin sensitivity.

Side effects and interactions. 2 medication interactions listed. Serious: Pancreatitis (rare).

Stacking. Pairs well with Resistance training and high protein. Avoid combining with Personal or family history of MTC or MEN2.

Common forms. Available as Once-weekly subcutaneous injection.

Community. Experiences from people who have tried Tirzepatide. Anecdotes are not medical advice.

Tirzepatide. Dual GIP and GLP-1 receptor agonist with stronger weight-loss effects than GLP-1 alone.

39-residue chainC225H348N48O68 · 4813 g/mol

What it is

Tirzepatide is a synthetic peptide engineered to bind both the GIP and GLP-1 receptors with an extended half-life suitable for weekly dosing.

Also called

MounjaroZepbound

How it works

Co-activates GIP and GLP-1 receptors, producing additive insulinotropic, satiety, and adipose-tissue effects greater than GLP-1 alone.

Pathways

  • GLP-1 receptor agonism
  • GIP receptor agonism
  • Hypothalamic satiety signaling

Effects

  • ↓Appetite and body weight decreases
  • ↑Insulin secretion (glucose-dependent) increases
  • +Adipose energy partitioning optimizes

What the research supports

Largest documented weight loss for an injectable peptide therapypreclinical
Strong A1c improvementspreclinical
Cardiometabolic benefitspreclinical

Strong: consistent results across large trials or meta-analyses. Moderate: several trials, mostly positive. Limited: small or mixed studies. Preclinical: animal or cell research only.

Hormonal impact

↑Insulinincreases
↓Glucagondecreases
↑GIP signalingincreases
~Leptin sensitivitymodulates

Side effects & interactions

Common side effects

  • Nausea
  • Diarrhea
  • Constipation

Serious

  • Pancreatitis (rare)
  • Thyroid C-cell tumor risk (rodent data)

Medication interactions

Insulin or sulfonylureasmoderate

Hypoglycemia risk; dose adjustment expected.

Oral contraceptivesmoderate

Slowed gastric emptying can reduce absorption.

Check any supplement–medication combination with your pharmacist before starting.

Combines with

Pairs well

  • Resistance training and high proteinPreserves lean mass during weight loss.

Avoid combining

  • Personal or family history of MTC or MEN2Boxed contraindication shared with GLP-1 class.

Common forms

  • Once-weekly subcutaneous injection

Discussion

Loading discussion…